Vaxinano
Vaxinano is a clinical stage biotech company dedicated to developing innovative nasal and thermostable vaccines for human and animal health. Founded in 2016, the company leverages nanomedicine and proprietary vaccine platforms to address unmet needs in infectious diseases, with a focus on mucosal immunotherapy and vaccine delivery systems. Vaxinano collaborates globally, supports wildlife conservation through its WildVax program, and has received recognition for its impactful contributions to vaccine technology.
Industries
Nr. of Employees
small (1-50)
Vaxinano
84 rue du docteur Yersin, Parc Eurasanté, 59120 Loos, FRANCE
Products
Nasal toxoplasmosis vaccine candidate (antigen-loaded lipidated nanoparticles)
Inactivated-antigen or protein vaccine candidate formulated in maltodextrin-based lipid-core nanoparticles for intranasal administration to induce Th1/Th17 cellular immunity and prevent/reactivate Toxoplasma gondii infection.
Canine leishmaniasis vaccine candidate (nasal immunotherapy)
Nasally administered immunotherapeutic vaccine formulation evaluated in naturally infected dogs to strengthen deficient immune responses against Leishmania infantum.
Nasal toxoplasmosis vaccine candidate (antigen-loaded lipidated nanoparticles)
Inactivated-antigen or protein vaccine candidate formulated in maltodextrin-based lipid-core nanoparticles for intranasal administration to induce Th1/Th17 cellular immunity and prevent/reactivate Toxoplasma gondii infection.
Canine leishmaniasis vaccine candidate (nasal immunotherapy)
Nasally administered immunotherapeutic vaccine formulation evaluated in naturally infected dogs to strengthen deficient immune responses against Leishmania infantum.
Services
Coordination and delivery of intranasal vaccination campaigns for endangered and captive species in partnership with zoological institutions.
Commercial licensing and collaborative R&D agreements with animal-health companies including transfer of vaccine candidates and co-development funding.
Coordination and delivery of intranasal vaccination campaigns for endangered and captive species in partnership with zoological institutions.
Commercial licensing and collaborative R&D agreements with animal-health companies including transfer of vaccine candidates and co-development funding.
Expertise Areas
- Mucosal vaccine development
- Nanoparticle vaccine formulation
- Thermostable vaccine formulation and distribution
- Preclinical animal models for infectious diseases
Key Technologies
- Mucosal (intranasal) vaccine delivery
- Double-core nanoparticle platforms
- Maltodextrin-based lipid-core nanoparticles
- Thermostable vaccine formulations
News & Updates
Vaxinano was awarded the Impact Prize at the Tech For Future event, organized by La Tribune and BNP Paribas, recognizing its innovative contributions in biotech.
Vaxinano has entered into an exclusive license agreement with Vétoquinol to develop its canine leishmaniasis vaccine candidate using its proprietary nanoparticle technology.
Vaxinano announced it secured €6 million in funding to support the development and clinical testing of its nasal vaccines.
Vaxinano presents its latest vaccine research and development activities utilizing its innovative STELLAR-NP platform.
Vaxinano has collaborated with Pairi Daiza Zoo to vaccinate animals against toxoplasmosis, demonstrating its vaccine's efficacy in wildlife conservation.
A study demonstrating how nasal vaccination with killed Toxoplasma gondii loaded in maltodextrin nanoparticles can induce protective immune responses.
Vaxinano was awarded the Impact Prize at the Tech For Future event, organized by La Tribune and BNP Paribas, recognizing its innovative contributions in biotech.
Vaxinano has entered into an exclusive license agreement with Vétoquinol to develop its canine leishmaniasis vaccine candidate using its proprietary nanoparticle technology.
Vaxinano announced it secured €6 million in funding to support the development and clinical testing of its nasal vaccines.
Vaxinano presents its latest vaccine research and development activities utilizing its innovative STELLAR-NP platform.
Vaxinano has collaborated with Pairi Daiza Zoo to vaccinate animals against toxoplasmosis, demonstrating its vaccine's efficacy in wildlife conservation.
A study demonstrating how nasal vaccination with killed Toxoplasma gondii loaded in maltodextrin nanoparticles can induce protective immune responses.